Long-lasting severe immune dysfunction in Ebola virus disease survivors

Aurélie Wiedemann, Emile Foucat, Hakim Hocini, Cécile Lefebvre, Boris P. Hejblum, Mélany Durand, Miriam Krüger, Alpha Kabinet Keita, Ahidjo Ayouba, Stéphane Mély, José-Carlos Fernandez, Abdoulaye Touré, Slim Fourati, Claire Lévy-Marchal, Hervé Raoul, Eric Delaporte, Lamine Koivogui, Rodolphe Thiébaut, Christine Lacabaratz and Yves Lévy ()
Additional contact information
Aurélie Wiedemann: Université Paris-Est Créteil
Emile Foucat: Université Paris-Est Créteil
Hakim Hocini: Université Paris-Est Créteil
Cécile Lefebvre: Université Paris-Est Créteil
Boris P. Hejblum: Vaccine Research Institute (VRI)
Mélany Durand: Vaccine Research Institute (VRI)
Miriam Krüger: Vaccine Research Institute (VRI)
Alpha Kabinet Keita: Montpellier University
Ahidjo Ayouba: Montpellier University
Stéphane Mély: US003 INSERM
José-Carlos Fernandez: Université Paris-Est Créteil
Abdoulaye Touré: Montpellier University
Slim Fourati: Laboratoire de Virologie
Claire Lévy-Marchal: INSERM
Hervé Raoul: US003 INSERM
Eric Delaporte: Montpellier University
Lamine Koivogui: Institut National de Santé Publique (INSP)
Rodolphe Thiébaut: Vaccine Research Institute (VRI)
Christine Lacabaratz: Université Paris-Est Créteil
Yves Lévy: Université Paris-Est Créteil

Nature Communications, 2020, vol. 11, issue 1, 1-11

Abstract: Abstract Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in ‘inflammation’ and ‘antiviral’ pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of “chronic Ebola virus disease (CEVD)”.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17489-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17489-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17489-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().